Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal...
Amgen
Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five...
After a busy first day featuring headlines from a who’s who of leading biopharma companies,...
Amgen is getting down with Disco Pharmaceuticals, commissioning the German outfit to work on cancer...
Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer...
Following a middling phase 3 readout for gastric cancer candidate bemarituzumab, Amgen has now stopped...
Veeva Systems has unveiled its first big biotech pact since thawing relations with one-time adversary...